BioCardia, Inc. (6JU.F)
| Previous Close | 0.3260 |
| Open | 0.3240 |
| Bid | 0.3360 x N/A |
| Ask | 0.3680 x N/A |
| Day's Range | 0.3240 - 0.3380 |
| 52 Week Range | 0.0100 - 2.5600 |
| Volume | |
| Avg. Volume | 116 |
| Market Cap | 9.581M |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5100 |
| Earnings Date | May 08, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.17 |
GlobeNewswireBioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized TrialSUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. The Comp
Insider MonkeyInsiders Are Buying These 11 Penny Stocks
In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024 in the red, driven by rising treasury yields, broader volatility and uncertainty around rate cuts […]
Insider MonkeyBioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript March 27, 2024 BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11. BCDA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. […]
